ArticleFrontiers in endocrinology2022
Effects of Icariin on Modulating Gut Microbiota and Regulating Metabolite Alterations to Prevent Bone Loss in Ovariectomized Rat Model.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Causal effects of specific gut microbiota on bone mineral density: a two-sample Mendelian randomization study.Frontiers in endocrinology · 2023Pooled it
- Review
- Traditional Chinese Medicine for osteoporosis management: from molecular mechanisms to drug discovery.Chinese medicine · 2026Review
- Gut-bone axis: mechanisms and intervention effects of Chinese botanical drugs in osteoporosis management.Frontiers in pharmacology · 2026Review
- Psychological stress and gut microbiota regulation of osteoarthritis progression: mechanisms and therapeutic strategies.Frontiers in microbiology · 2026Review
- Multi-system Mechanisms in the Anti-osteoporotic Effects of Herbal Natural Products.Endocrine, metabolic & immune disorders drug targets · 2026Review
- The Mediating Role of Bioactive Molecules in Gut Microbiota-Bone Metabolism Crosstalk.Nutrients · 2025Review
- Gut microbiota and ovarian diseases: a new therapeutic perspective.Journal of ovarian research · 2025Review
- Study on the mechanism of Shuanghe decoction against steroid-induced osteonecrosis of the femoral head: insights from network pharmacology, metabolomics, and gut microbiota.Journal of orthopaedic surgery and research · 2025Article
- Effects of traditional Chinese medicine Zuo-Gui-Wan on gut microbiota in an osteoporotic mouse model.Journal of orthopaedic surgery and research · 2025Article
- Icariin against osteoporosis: a review of advances in molecular mechanisms to biomedical applications.Frontiers in pharmacology · 2025Review
- Potential efficacy and mechanisms of icariin for the animal model of osteonecrosis of the femoral head.Frontiers in pharmacology · 2025Article
- Intestinal overexpression ofFrontiers in cellular and infection microbiology · 2025Article
- Fecal microbiota transplantation alleviates lipopolysaccharide-induced osteoporosis by modulating gut microbiota and long non-coding RNAFrontiers in cellular and infection microbiology · 2025Article
- Qing'e Pills Ameliorates Osteoporosis by Regulating Gut Microbiota and Th17/Treg Balance in Ovariectomized Rats.Journal of inflammation research · 2025Article
- The gut-bone axis in osteoporosis: a multifaceted interaction with implications for bone health.Frontiers in endocrinology · 2025Review
- The therapeutic potential of icariin in the intervention of bone and joint diseases through multiple pathways: a narrative review.Frontiers in pharmacology · 2025Review
- Natural bioactive products in the regulation of bone metabolism and regeneration.Frontiers in pharmacology · 2025Review
- Salt sensitivity potentiates high-salt diet-induced intestinal barrier disruption and gut microbiome dysbiosis in rats.Frontiers in microbiology · 2025Article
- Extract ofCells · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis (PMOP) is an estrogen deficiency-induced bone loss, which has been shown an association with an altered gut microbiota (GM). Gut microbiota-bone axis has been recognized as a crucial mediator for bone homeostasis. Icariin (ICA) is an effective agent to delay bone loss by regulating the bone homeostasis. Thus, we hypothesize that ICA can prevent bone loss by modulating GM and regulating metabolite alterations. The effects of ICA on bone metabolism improvement in ovariectomized (OVX) rats and their relationships with the GM and fecal metabolites were investigated. Micro-computed tomography (micro-CT) and hematoxylin-eosin (HE) staining showed a typical bone boss in OVX group, while ICA or estradiol (E2) administration exhibited positive effects on bone micro-architecture improvement. The GM such as Actinobacteria, Gammaproteobacteria, Erysipelotrichi, Erysipelotrichales, Enterobacteriales, Actinomycetales,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.